Clinical Trial Update: VEN+IDAC vs IDAC in AML [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing venetoclax plus IDAC versus IDAC alone in acute myeloid leukemia is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• Venclexta (venetoclax)

Snippet

Sponsor: Guangdong Second Provincial General Hospital | Conditions: AML (Acute Myelogenous Leukemia) | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION